Vir Biotechnology, Inc.

Valuation Analysis

About the Company

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii

Vir Biotechnology, Inc. Stock at a Glance

Vir Biotechnology, Inc. (VIR) is currently trading at $8.61 with a market capitalization of $1.5B. The 52-week range spans from $4.16 to $11.66; the current price is 26.2% below the yearly high.

💰 Dividend

Vir Biotechnology, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

9 analysts rate Vir Biotechnology, Inc. (VIR) on consensus: Strong Buy. The average price target is $21.56, implying +150.35% from the current price. Analyst price targets range from $16.00 to $30.00.

Vir Biotechnology, Inc.: The Investment Case in Detail

Vir Biotechnology, Inc. (VIR) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Strong Buy with an average price target implying roughly 150.35% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Short interest sits at 11% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

What to Watch Next

• The analyst consensus price target implies 150.35% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to above-average price swings, elevated short interest (11%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Vir Biotechnology, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.